Welcome to our dedicated page for Arcadia Bioscien SEC filings (Ticker: RKDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Arcadia Biosciences’ biotech disclosures can feel like decoding a genetics textbook—cash-runway tables, regulatory milestones, and crop-trait data are buried in hundreds of pages. Our AI-powered platform turns that complexity into clarity, delivering Arcadia Biosciences SEC filings explained simply so you can focus on decisions, not document digging.
Whether you need the Arcadia Biosciences annual report 10-K simplified for pipeline risks, an Arcadia Biosciences quarterly earnings report 10-Q filing for R&D spending, or the latest Arcadia Biosciences 8-K material events explained after a hemp-license update, Stock Titan serves every form the moment it hits EDGAR.
- Instant alerts on Arcadia Biosciences Form 4 insider transactions real-time to track executive moves
- Concise AI summaries of GoodWheat revenue trends in each filing
Investors often ask, “How do I monitor Arcadia Biosciences insider trading Form 4 transactions?” or “Where are the cash-burn numbers in the 10-Q?” Our platform answers these questions automatically, highlighting:
- Segment revenue split between wheat, soy and hemp innovations
- Regulatory approvals that can trigger milestone payments
- Arcadia Biosciences proxy statement executive compensation details, clearly summarized
From Arcadia Biosciences earnings report filing analysis to understanding Arcadia Biosciences SEC documents with AI, we connect the dots between filing language and business impact. Real-time feeds, expert context and machine learning distill every 10-K, 10-Q, 8-K and S-1 into actionable insights—so you can gauge crop-trait momentum, monitor Arcadia Biosciences executive stock transactions Form 4, and stay ahead of material events without reading line-by-line.
Arcadia Biosciences (RKDA) disclosed several material corporate and accounting developments in its Form 10-Q. The company amended an Exchange Agreement and filed a Form S-4 related to an equity issuance, extending the agreements termination date to August 15, 2025. As of June 30, 2025 the company had 150,000,000 shares authorized and 1,367,040 shares issued and outstanding (1,364,940 at December 31, 2024).
The company treated the sale of its GoodWheat business as a discontinued operation under ASC 205-20, recognizing a $1,500 loss in the second quarter of 2024. A contingent liability tied to prior Anawah technology obligations of $2.0 million was eliminated as of June 30, 2025 after program abandonments and transfers. The company recorded an additional right-of-use asset and lease liability of $86,000 related to a lease renewal and later terminated that facility lease effective July 2024.
Equity plans changed: the 2015 Plan terminated for future awards in May 2025; 338,341 shares remained reserved under the 2015 Plan as of June 30, 2025. The company faces a Proposition 65-related BPA lawsuit amended May 23, 2025, and answered the complaint on July 22, 2025, denying liability. Managements CODM evaluates performance using consolidated net (loss) income.
FAQ
What is the current stock price of Arcadia Bioscien (RKDA)?
What is the market cap of Arcadia Bioscien (RKDA)?
